This Italian company specializing in the prescription of skin care, the formulation of highly innovative products and clinical studies, is offering a partial sale of its shares. With a recent turnover of 4 million euros, the company forecasts growth to more than 6 million euros for 2022. Its export sales, representing 10% of the total, have seen constant growth since 2018 , with distributors in Asia. The firm, established in the mid-1990s, has a growing portfolio of clinically tested brands, ranging from OTC products to medical devices. Currently, the company is seeking strategic investors to support its expansion. The firm is distinguished by its focus on the formulation and manufacturing of R&D-intensive skin care products, with 70% of sales coming from OTC and Rx products. The remaining 30% come from the gynecological and anti-infectious line. With strong formulation capabilities, the company has access to an extensive network of dermatologists, gynecologists, sales representatives and pharmacies across the country. The company recently launched a new hair loss product, with the aim of gaining a share of the estimated \u20ac100 million alopecia market.<\/p>\n","protected":false},"author":1,"comment_status":"closed","ping_status":"closed","template":"","class_list":["post-4140","rtcl_listing","type-rtcl_listing","status-publish","hentry","rtcl_category-personal-services","listing-item","rtcl-listing-item"],"yoast_head":"\n